

Sixten Borg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/618612/publications.pdf>

Version: 2024-02-01

27
papers

1,296
citations

567281

15
h-index

526287

27
g-index

27
all docs

27
docs citations

27
times ranked

1808
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | New Diabetes Questionnaire to add patients'™ perspectives to diabetes care for adults with type 1 and type 2 diabetes: nationwide cross-sectional study of construct validity assessing associations with generic health-related quality of life and clinical variables. <i>BMJ Open</i> , 2020, 10, e038966. | 1.9 | 4 |
| 2 | Quality of life in chronic conditions using patient-reported measures and biomarkers: a DEA analysis in type 1 diabetes. <i>Health Economics Review</i> , 2019, 9, 31. | 2.0 | 4 |
| 3 | Health-related quality of life and glycaemic control among adults with type 1 and type 2 diabetes – a nationwide cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 141. | 2.4 | 36 |
| 4 | Patient-reported outcome and experience measures for diabetes: development of scale models, differences between patient groups and relationships with cardiovascular and diabetes complication risk factors, in a combined registry and survey study in Sweden. <i>BMJ Open</i> , 2019, 9, e025033. | 1.9 | 22 |
| 5 | A disease-specific questionnaire for measuring patient-reported outcomes and experiences in the Swedish National Diabetes Register: Development and evaluation of content validity, face validity, and test-retest reliability. <i>Patient Education and Counseling</i> , 2018, 101, 139-146. | 2.2 | 30 |
| 6 | Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. <i>International Journal of COPD</i> , 2017, Volume 12, 3183-3194. | 2.3 | 30 |
| 7 | Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?. <i>Value in Health</i> , 2016, 19, 800-810. | 0.3 | 11 |
| 8 | Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. <i>Acta Oncol³gica</i> , 2016, 55, 554-560. | 1.8 | 14 |
| 9 | Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. <i>Journal of Medical Economics</i> , 2015, 18, 492-501. | 2.1 | 22 |
| 10 | Patient-Reported Outcome Measures and Risk Factors in a Quality Registry: A Basis for More Patient-Centered Diabetes Care in Sweden. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 12223-12246. | 2.6 | 17 |
| 11 | Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. <i>Value in Health</i> , 2014, 17, 525-536. | 0.3 | 41 |
| 12 | Budget Impact Analysis of Surgical Treatment for Obesity in Sweden. <i>Scandinavian Journal of Surgery</i> , 2012, 101, 190-197. | 2.6 | 7 |
| 13 | Drug and treatment costs in Parkinson's™ disease patients in Sweden. <i>Acta Neurologica Scandinavica</i> , 2012, 125, 142-147. | 2.1 | 37 |
| 14 | A Maximum Likelihood Estimator of a Markov Model for Disease Activity in Crohn's™ Disease and Ulcerative Colitis for Annually Aggregated Partial Observations. <i>Medical Decision Making</i> , 2010, 30, 132-142. | 2.4 | 8 |
| 15 | Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort. <i>European Journal of Health Economics</i> , 2009, 10, 217-226. | 2.8 | 17 |
| 16 | The Swedish cost burden of overweight and obesity – evaluated with the PAR approach and a statistical modelling approach. <i>Pediatric Obesity</i> , 2008, 3, 51-57. | 3.2 | 22 |
| 17 | The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: A Markov model. <i>Acta Oncol³gica</i> , 2008, 47, 1009-1017. | 1.8 | 11 |
| 18 | Retrospective incremental cost analysis of a hospital-based COPD Disease Management Programme in Sweden. <i>Health Policy</i> , 2007, 81, 309-319. | 3.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population-Based Study from Copenhagen, Denmark. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 481-489. | 1.9 | 340 |
| 20 | Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-Receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: A decision-analytic model. <i>Clinical Therapeutics</i> , 2006, 28, 1947-1959. | 2.5 | 9 |
| 21 | Obesity, Survival, and Hospital Costs—Findings from a Screening Project in Sweden. <i>Value in Health</i> , 2005, 8, 562-571. | 0.3 | 48 |
| 22 | Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: Comparative analysis of drug utilization, costs, and hematologic response. <i>Advances in Therapy</i> , 2005, 22, 208-224. | 2.9 | 14 |
| 23 | Cost Differences for COPD With and Without Physician-Diagnosis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 427-434. | 1.6 | 15 |
| 24 | A Computer Simulation Model of the Natural History and Economic Impact of Chronic Obstructive Pulmonary Disease. <i>Value in Health</i> , 2004, 7, 153-167. | 0.3 | 80 |
| 25 | The Impact of Exacerbations on the Asthmatic Patient's Preference Scores. <i>Journal of Asthma</i> , 2003, 40, 615-623. | 1.7 | 30 |
| 26 | Costs of COPD in Sweden According to Disease Severity. <i>Chest</i> , 2002, 122, 1994-2002. | 0.8 | 161 |
| 27 | The costs of exacerbations in chronic obstructive pulmonary disease (COPD). <i>Respiratory Medicine</i> , 2002, 96, 700-708. | 2.9 | 259 |